Welcome to EpilepsyU.com a social network dedicated to the epilepsy community

Cannabis

Zynerba’s cannabis-based epilepsy gel fails in phase 2 trial

Zynerba Pharmaceuticals has reported that its cannabis-based epilepsy gel ZYN002 (cannabidiol [CBD] gel) has failed to meet the primary point in a phase 2 clinical trial. The trial dubbed as STAR 1 was held in 188 adult epilepsy patients with focal seizures across 14 sites in Australia and New Zealand. When compared to placebo, ZYN002 during the treatment period could not show a statistically significant decrease in focal seizures in comparison to the baseline period for either the high or low dose cohorts. STAR expands to Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy. The patients in the phase 2 trial were randomized to be treated during a 12-week period for every 12 hours with either 195mg of ZYN002 4.2% CBD gel, 97.5mg of ZYN002 4.2% CBD gel or placebo gel. The primary...

The DEA just gave a big boost to a cannabis-based seizure drug

We are often judged by the company we keep, even unfairly. For decades, that has been the fate of cannabidiol, a chemical compound that has the bad luck to occur naturally in marijuana, the world’s most controversial plant. Because cannabidiol is subject to the same tight legal restrictions on personal and scientific use as is marijuana, its potential medical benefits have been underappreciated — at least up until now.

CBD FOR EPILEPSY: To be available in Florida NEXT WEEK!

After 2 years of delays, appeals and uncertainty about availability, high-CBD, low-THC Medical Cannabis grown in Florida will finally be available next week to patients with prescriptions. Trulieve, located in Tallahassee, Florida, have announced that they have received the first formal authorization from the Florida DOH (Department of Health) to commence sales and dispensary of medicinal cannabis products. These CBD products are approved for persons with uncontrollable seizures and cancer and possibly other conditions. Children with Dravet syndrome and intractable and other hard-to-treat types of Epilepsy are expected to be greatly helped by the availability of high-CBD cannabis derived medicine. For more information check out Orlando Weekly, Miami Herald, or Orlando Sentinel and many oth...

Early promise for cannabis extract treatment in epilepsy

A preliminary, open-label study suggests that cannabidiol may be a useful adjunctive treatment in adults and children with intractable epilepsy. The multicentre trial, involving 214 patients aged between 1 and 30 years, demonstrated acceptable safety and promising efficacy in patients with treatment-resistant epilepsy. The patients took twice-daily 99% pure oil-based cannabidiol extract, starting at a dose of 2–5 mg/kg per day and titrated up to a maximum dose of 25 mg/kg per day during 12 weeks of treatment. There were 162 patients in the safety analysis, 79% of whom had at least one adverse event, the most frequent of which were somnolence (25%), decreased appetite (19%) and diarrhoea (19%). The most common event thought by the investigators to have a possible connection to the study dru...

CBD Treatment Gaining Legitimacy Through Research

Encouraging results from cannabidiol trial for treatment-resistant epilepsy Cannabidiol (CBD), a medical marijuana derivative, was effective in reducing seizure frequency and well-tolerated and safe for most children and young adults enrolled in a year-long study led by epilepsy specialists at NYU Langone Medical Center. These latest findings provide the first estimates of safety, tolerability and efficacy of prescription CBD in children and adults with severe, highly treatment-resistant epilepsy. Led by Orrin Devinsky, MD, professor of neurology, neurosurgery, and psychiatry and director of the Comprehensive Epilepsy Center at NYU Langone, the study is published in the December 23 issue of Lancet Neurology. While early findings have been released at medical meetings — including the ...

Synthetic Cannabis Treatment Tested on Humans

Experimental synthetic [Cannabis] therapy for epilepsy being tested on humans Zynerba Pharmaceuticals Inc. said Tuesday it has started the company’s first human testing of one of its experimental synthetic cannabinoid treatments.

Cannabis Research Journal Supports Obama’s Statement On Medical Cannabis

Mary Ann Liebert, publisher of the newly launched peer-reviewed open access journalCannabis and Cannabinoid Research, strongly supports President Obama’s statement that “…carefully prescribed medical use of marijuana may in fact be appropriate and we should follow the science as opposed to ideology on this issue,” when asked about a pending Senate bill seeking to change federal law regarding state-legalized medical marijuana programs. Cannabis and Cannabinoid Research, a fully open access journal will be the authoritative source for research, discussion, and debate. Mary Ann Liebert, Inc., publishers will publish the Journal under the Creative Commons Attribution 4.0 (CC BY) license to ensure broad dissemination and participation. Cannabis and Cannabinoid Research w...

ACCESS TO CBD FINALLY MAKES ADVANCE IN FLORIDA

By the end of 2015, patients in Florida may finally have access to CBD under a bill that was signed into law in November, 2014 by Governor Rick Scott. A judge in Tallahassee dismissed the final challenge to the rule Wednesday night. The Florida Department of Health, which developed the rule, is expected to start accepting applications within three weeks from eligible growers for the strain of marijuana that is low in euphoria-inducing tetrahydrocannabinol, or THC, and high in cannabidiol, or CBD. Growers could start selling to eligible patients who are put on a state-run “compassionate use registry” within months. “Today’s ruling allows the department to move forward with implementing the Compassionate Medical Cannabis Act, approved by the Legislature in 2014,”...

CBD EXPLAINED: Study shows how cannabidiol works within cells

A team of Stony Brook University researchers have identified fatty acid binding proteins (FABPs) as intracellular transporters for two ingredients in marijuana, THC and CBD (cannabidiol). The finding, published early online in the Journal of Biological Chemistry, is significant because it helps explain how CBD works within the cells. Recent clinical findings have shown that CBD may help reduce seizures and could be a potential new medicine to treat pediatric treatment-resistant epilepsy. CBD differs from THC in that it is not psychoactive and does not bind to cannabinoid receptors. Some children who are resistant to conventional antiepileptic drugs have been reported to show improvement with oral CBD treatment. The Stony Brook research team found that three brain FABPs carry THC and CBD fr...

Advances in Epilepsy 2014, A Year in Review

2014 saw many changes in the understanding and treatments for epilepsy. As you all are well aware, Cannabis treatments became a major topic over the past few years, culminating in 2014 with many states passing compassionate care laws, like Florida’s Charlotte’s Web Bill (which won’t go into effect until 2015). Here is a roundup of some of the highlights from 2014. CBD FOR EPILEPSY While there is a growing body of evidence to support the treatment of seizures with cannabis, clinical trials are just beginning to shed some light on the effectiveness of CBD, one component of Cannabis that popular thought attributes to help seizures. EpilepsyU Conducted a CBD for Epilepsy Survey to gauge the public’s response to cannabis treatments and posted the results in easy to under...

A New Candian Study Shows Dramatic Success With CBD Treatment for Epilepsy

PRESS RELEASE: VANCOUVER, British Columbia, Nov. 24, 2014 (GLOBE NEWSWIRE) — A new study from Orrin Devinsky, MD, of the New York University School of Medicine, suggests that Cannabidiol (CBD) may radically reduce seizures in patients with epilepsy. Dr. Devinsky administered cannabidiol to 23 patients with treatment-resistant epilepsy. Thirty-nine percent of the patients saw their seizure rates drop by more than 50%. Four patients (17%) had no seizures for the last month of treatment. Lexaria (CSE:LXX) (OTCQB:LXRP) has acquired 51% of PoViva Corp, an innovative health company developing Cannabidiol (CBD)-infused products. Lexaria may increase its ownership position to 75% at a later date. “Most CBD’s taste awful,” stated Lexaria CEO and Chairman Chris Bunka in an ex...

Initial Data on ‘Pharma Grade’ Cannabidiol in Epilepsy

Initial data from an open-label study in treatment-resistant epilepsy of pharmaceutical-grade cannabidiol — the nonpsychoactive ingredient in marijuana that is believed to be responsible for its antiepileptic action — suggest that it reduces seizure rate by about 30%. The product, said to be 98% pure cannabidiol, in development under the brand name Epidiolex by GW Pharmaceuticals, which funded this study, was associated with a greater than 50% reduction in seizures in 39% of patients. Lead investigator, Orrin Devinsky, MD, New York University School of Medicine, said he thought the results were “encouraging.” “There appears to be potential for real benefit,” he told Medscape Medical News. A second study of patients using many different types of medical marijuana has...

Lost Password

Register